spacer
home > white papers > Using Device Strategy to Drive R&D Productivity - Phillips-Medisize
WHITE PAPERS
logo_Phillips-Mk.jpg

Phillips-Medisize

phone +31 252 576 888
email eu_sales@phillipsmedisize.com
web http://www.phillipsmedisize.com
email Edisonstraat 1 Hillegom 2181 AB

Using Device Strategy to Drive R&D Productivity

Biopharmaceutical companies face sustained pressure from all sides to develop better products at lower costs, delivering value to patients, payers and shareholders. Healthcare costs are rising globally at an unsustainable level, putting the entire healthcare delivery system under pricing pressure. Biopharmaceutical companies have become popular targets, evidenced by increasing scrutiny on prescription medicine prices, even though spending on medicine accounts for only about ~10% of overall spend.
Using Device Strategy to Drive R&D Productivity
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

NEUWAY Pharma and Cobra Biologics collaborate to develop GMP grade Engineered Protein Capsules (EPCs) manufacturing process

International CDMO of biologics and pharmaceuticals, together with a biopharma company developing drugs for orphan diseases, announce the conclusion of a Service Agreement relating to Engineered Protein Capsules
More info >>


White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>


Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement